10mg cialis vs 20mg cialis

pmid:17087800, doi:10.1111/j.1743-6109.2006.00387.x, comparative study, controlled clinical trial, randomized controlled trial, research support, non-u.s. gov't, ken marumo, takeshi imaoka, james mcgill, adult, carbolines / adverse effects, carbolines / therapeutic use*, dose-response relationship, drug, double-blind method, drug administration schedule, erectile dysfunction / drug therapy*, humans, japan, male, middle aged, patient satisfaction*, penile erection*, phosphodiesterase inhibitors / adverse effects, phosphodiesterase inhibitors / therapeutic use*, research design, severity of illness index, tadalafil, treatment outcome, vasodilator agents / therapeutic use, pubmed abstract, nih, nlm, ncbi, national institutes of health, national center for biotechnology information, national library of medicine, medline

A comparison of the efficacy and tolerability of tadalafil 10 mg and 20 mg in Japanese patients with severe erectile dysfunction.
Introduction: Tadalafil is a phosphodiesterase type 5 inhibitor with documented efficacy in the treatment of erectile dysfunction (ED).
Aim: To compare the efficacy and tolerability of tadalafil 10 mg and 20 mg in men with severe ED.
Methods: A prespecified subgroup analysis was conducted to compare the efficacy of tadalafil 10 and 20 mg measured by the International Index of Erectile Function (IIEF) erectile function (EF) domain and Sexual Encounter Profile (SEP) among patients with severe ED (EF domain score = 1-10) in a Japanese placebo-controlled study (PCT). We also analyzed the efficacy of the two doses in men with severe ED post hoc by pooling data from three tadalafil clinical trials that evaluated these doses using a similar study design (three placebo-controlled trials), and evaluated (post hoc) the presence of organic comorbidities in patients with different levels of response to tadalafil 10 or 20 mg.
Main outcome measures: Mean change in the IIEF-EF domain and mean per-patient changes in percent “yes” responses to SEP Question 2 (SEP2) and Question 3 (SEP3).
Results: Patients with severe ED in the Japanese study experienced numerically greater increases (improvements) when taking tadalafil 20 mg compared with 10 mg in the IIEF-EF domain (14.3 vs. 12.4; P = 0.355), SEP2 (60% vs. 57%; P = 0.781), and SEP3 (61% vs. 49%, P = 0.196). When sufficiently powered, these observations reached statistical significance in the three PCTs: patients with severe ED experienced greater increases when taking tadalafil 20 mg compared with 10 mg in the IIEF-EF domain (13.6 vs. 10.4; P = 0.014) and SEP3 (56% vs. 43%, P = 0.019). Both doses were well tolerated.
Conclusions: Patients with severe ED, and especially those with an organic comorbidity, may derive greater clinical benefits from tadalafil 20 mg compared with 10 mg.
Similar articles.
Buvat J, van Ahlen H, Schmitt H, Chan M, Kuepfer C, Varanese L. Buvat J, et al. J Sex Med. 2006 May;3(3):512-20. doi: 10.1111/j.1743-6109.2006.00249.x. J Sex Med. 2006. PMID: 16681477 Clinical Trial.
Porst H, Gacci M, B├╝ttner H, Henneges C, Boess F. Porst H, et al. Eur Urol. 2014 Feb;65(2):455-64. doi: 10.1016/j.eururo.2013.09.037. Epub 2013 Oct 2. Eur Urol. 2014. PMID: 24119319.
Broderick GA, Donatucci CF, Hatzichristou D, Torres LO, Valiquette L, Zhao Y, Loughney K, Sides GD, Ahuja S. Broderick GA, et al. J Sex Med. 2006 Jul;3(4):668-675. doi: 10.1111/j.1743-6109.2006.00273.x. J Sex Med. 2006. PMID: 16839323.
Montorsi F, Padma-Nathan H, Glina S. Montorsi F, et al. Urology. 2006 Sep;68(3 Suppl):26-37. doi: 10.1016/j.urology.2006.06.027. Urology. 2006. PMID: 17011373 Review.
Curran M, Keating G. Curran M, et al. Drugs. 2003;63(20):2203-12; discussion 2213-4. doi: 10.2165/00003495-200363200-00004. Drugs. 2003. PMID: 14498756 Review.
Cited by.
Guo YL, Viswanathan VP, Chiang HS, Choi HK, Yip AW, Shen W, Kopernicky V. Guo YL, et al. Asian J Androl. 2009 Jul;11(4):423-33. doi: 10.1038/aja.2009.11. Epub 2009 Apr 20. Asian J Androl. 2009. PMID: 19377488 Free PMC article.
Publication types.